Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.1052W HIGH $24.28
Volume
3.23 M
Value Traded
70.62 M
Short % Float
13.37%
+6.78%Week
+0.25%1 Month
-15.06%3 Month
-7.47%6 Month
-29.31%5 Year
-29.31%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.54 B
EPS (TTM)
-0.82
P/E Ratio
-
Ent. Value
5.16 B
Total Shares
349.62 M
Float Shares
247.18 M
Insiders
29.33%
Institutions
60.93%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ERAS Catalyst Timeline
Dated clinical, regulatory and corporate events for Erasca, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Erasca, Inc.
338Total events
12Upcoming
83Tier-1 (high impact)
2020 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Fast Track DesignationERAS-0015Designation
FDA granted Fast Track Designation to ERAS-0015 for metastatic pancreatic adenocarcinoma
metastatic pancreatic adenocarcinomasource ↗
▲Full ResultsERAS-0015Clinical Data
Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC
2L+ KRAS G12X PDACsource ↗
▲Topline ReadoutERAS-0015Clinical Data
First dose escalation combination cohort data for ERAS-0015 with panitumumab
metastatic colorectal cancersource ↗
▲Topline ReadoutERAS-0015Clinical Data
Updated preliminary data from AURORAS-1 Phase 1 trial reported
RAS-mutant solid tumorssource ↗
▼IP Litigation RulingERAS-0015IP / Competition
Securities class action lawsuit filed against Erasca for alleged false statements regarding ERAS-0015
RAS-mutated solid tumorssource ↗
◆Oral PresentationPresentation
Erasca management to present at Jefferies Global Healthcare Conference
◆Oral PresentationPresentation
Erasca management to present at Bank of America Securities Health Care Conference
▲Partnership / LicenseERAS-0015Corporate
Clinical trial collaboration and supply agreement with Merck for ERAS-0015 + KEYTRUDA
RAS-mutant solid tumorssource ↗
▲Partnership / LicenseERAS-0015Corporate
Clinical Trial Collaboration and Supply Agreement with Merck for ERAS-0015 + KEYTRUDA
▼IP Litigation RulingERAS-0015IP / Competition
Revolution Medicines alleges ERAS-0015 infringes patent and involves trade secret misappropriation
cancerssource ↗
◆Topline ReadoutERAS-0015Clinical Data
Preliminary Phase 1 dose-escalation data for ERAS-0015 announced
▼IP Litigation RulingERAS-0015IP / Competition
RevMed challenges Erasca's IP claims for ERAS-0015
RAS-mutant solid tumorssource ↗
▼Serious Ae Or DeathERAS-0015Safety
Patient death after ERAS-0015 treatment
RAS-mutant solid tumorssource ↗
◆Oral PresentationERAS-0015Presentation
Conference call and webcast to discuss preliminary Phase 1 dose escalation data for ERAS-0015
RAS-mutant solid tumorssource ↗
◆Quarterly UpdateERAS-0015Corporate
Preliminary Phase 1 clinical data for ERAS-0015 reported in Form 8-K
▲First Patient DosedERAS-0015Trial
First patient dosed in ERAS-0015 monotherapy expansion cohort in US
RAS-mutant solid tumorssource ↗
▲Topline ReadoutERAS-0015Clinical Data
Preliminary dose escalation monotherapy data for ERAS-0015
KRAS G12X non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC)source ↗
▲Trial InitiationERAS-0015Trial
Initiation of monotherapy expansion cohorts for ERAS-0015
RAS-mutant solid tumorssource ↗
▲Partnership / LicenseERAS-0015Corporate
Erasca exercises option to expand license for ERAS-0015 to include China, Hong Kong, and Macau, securing worldwide rights
RAS-mutant solid tumorssource ↗
▲Partnership / LicenseCorporate
Clinical collaboration with Tango to evaluate ERAS-0015 + vopimetostat
MTAPdel RASm cancers (pancreatic, NSCLC)source ↗
▲Partnership / LicenseERAS-0015Corporate
Clinical Trial Collaboration and Supply Agreement with Tango Therapeutics for ERAS-0015 + vopimetostat
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference Fireside Chat
▲Patent GrantedERAS-4001IP / Competition
U.S. Patent No. 12,552,813 issued for ERAS-4001 composition of matter
KRAS-mutant solid tumorssource ↗
◆Oral PresentationPresentation
Guggenheim Emerging Outlook: Biotech Summit 2026 Fireside Chat
▲Patent GrantedERAS-4001IP / Competition
U.S. Composition of Matter Patent Issued for ERAS-4001
▼Equity OfferingCorporate
Closed upsized public offering of 25,875,000 shares at $10.00 per share, gross proceeds ~$258.8M
▼Equity OfferingCorporate
Pricing of upsized public offering of 22,500,000 shares at $10.00 per share
◆Oral PresentationPresentation
Erasca management presentation at 44th Annual J.P. Morgan Healthcare Conference
▼Trial DiscontinuedNaporafenibDiscontinuedTrial
Ceased enrollment of new patients in Phase 3 SEACRAFT-2 trial for naporafenib
NRASm melanomasource ↗
▲Enrollment UpdateERAS-0015Trial
Enrollment ahead of plan in AURORAS-1
RAS-mutant solid tumorssource ↗
▲First Patient DosedERAS-0015Trial
First patient dosed in ERAS-0015 combination dose escalation cohort in US
RAS-mutant solid tumorssource ↗
◆Topline ReadoutERAS-0015Clinical Data
Initial Phase 1 monotherapy data for ERAS-0015 expected in 1H 2026
RAS-mutant solid tumorssource ↗
▲Trial InitiationERAS-0015Trial
Initiation of combination dose escalation for ERAS-0015 with panitumumab
RAS-mutant solid tumorssource ↗
◆Oral PresentationPresentation
Erasca management to participate in fireside chat at Evercore Healthcare Conference
◆Oral PresentationPresentation
Guggenheim 2nd Annual Healthcare Innovation Conference Fireside Chat
▲Patent GrantedERAS-0015IP / Competition
U.S. Patent No. 12,458,647 issued for ERAS-0015 composition of matter
RAS/MAPK pathway-driven cancerssource ↗
▲Patent GrantedERAS-0015IP / Competition
U.S. composition of matter patent issued for ERAS-0015
RAS/MAPK pathway-driven cancerssource ↗
▲Patent GrantedERAS-0015IP / Competition
US patent covering composition of matter issued for ERAS-0015
RASm solid tumorssource ↗
◆Oral PresentationPresentation
Erasca management presentation at Morgan Stanley 23rd Annual Global Healthcare Conference
Past FDA Catalysts and PDUFA Decisions
How ERAS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-01-01 | ERAS-0015 (pan-RAS molecular glue) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C46 / 100
Pipeline Score
$780M
Pipeline Value
Richly Valued
Valuation Signal
6
Drugs Scored
0.2x
rNPV / MCap
Top 26%
Small Cap(rank 172 of 658)
Percentile Rank
Erasca, Inc. carries a moderate pipeline score (46/100), with $1.2B risk-adjusted pipeline value, led by ERAS-007 in Advanced Non-squamous Non-small-cell Lung Cancer (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ERAS-007 Small moleculeCompletedNCT05039177 | Metastatic Colorectal Cancer | Phase 1 | COMPLETED | 101 | Jan 26, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every ERAS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ERAS-0015 Fast Track | RAS-mutant solid tumors | Phase 1 | 2026-09-10 | favorable safety and tolerability results; confirmed and unconfirmed partial responses in multiple patients across multiple tumor types with different RAS mutations; confirmed partial responses at doses as low as 8 mg once daily (QD)Read More | Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR SymposiumRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Start Valerie Denise HardingDirector | Grant/Award | 29,888 29,888 held | $0.00 | 06/26/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ERAS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 10 % (-2.9 %) | 457.55 M | 24.98 M | 1.22% ( 300.00 K) |
ERAS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ERAS ranks across every disease it competes in
Competitive Position is a premium feature
See how ERAS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialERAS News
ERASErasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
Erasca, Inc. announced it will present updated clinical data for ERAS-0015 at the 38th EORTC-NCI-AACR Symposium. The oral presentation will include results from the AURORAS-1 Phase 1 trial, while a poster will showcase nonclinical combination data with ERAS-4001. The company aims to advance its therapies for RAS-mutant cancers.
Read more →ERASErasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
Erasca, Inc. will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The event will include a fireside chat and one-on-one investor meetings. A live audio webcast will be available, showcasing the company's commitment to developing therapies for RAS/MAPK pathway-driven cancers.
Read more →ERASErasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
Erasca, Inc. announced that the FDA has granted Fast Track Designation to its investigational drug ERAS-0015 for treating metastatic pancreatic adenocarcinoma. This designation follows promising Phase 1 trial results, showing significant clinical activity. The company plans to advance ERAS-0015 into Phase 3 trials and additional studies in lung cancer, with more data expected in early 2027.
Read more →ERASErasca Reports Second Quarter 2026 Business Updates and Financial Results
Erasca has reported promising updates for its ERAS-0015 program, highlighting significant monotherapy efficacy in patients with 2L+ KRAS G12X pancreatic ductal adenocarcinoma (PDAC). The data also indicates continued favorable tolerability. The company is advancing its combination program with panitumumab for colorectal cancer (CRC) towards three potentially registration-enabling trials.
Read more →ERASErasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Erasca, Inc. has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This move is part of their strategy to attract and retain talent as they focus on developing therapies for RAS/MAPK pathway-driven cancers. The announcement highlights the company's commitment to advancing precision oncology.
Read more →ERASErasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D
Erasca, Inc. has appointed Dr. Charles S. Fuchs as the new president of R&D, effective immediately. Dr. Fuchs brings over 30 years of oncology leadership and expertise in drug development. His appointment aims to advance Erasca's focus on therapies targeting RAS-driven cancers, addressing critical unmet needs in oncology. The company is preparing for future commercialization of its RAS-targeting franchise.
Read more →ERAS▼ -10.5%on this news
Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Erasca, Inc. has successfully closed an upsized public offering of 36,142,857 shares of common stock, generating gross proceeds of approximately $632.5 million. The offering included the full exercise of underwriters' options to purchase additional shares at $17.50 each. Proceeds will be utilized for research and development of cancer therapies and general corporate purposes.
Read more →ERAS▲ +8.9%on this newsshared move
Erasca Announces Pricing of Upsized Public Offering of Common Stock
Erasca, Inc. has announced the pricing of an upsized public offering of 31,428,572 shares at $17.50 per share, aiming to raise around $550 million. The proceeds will support research and development for therapies targeting RAS/MAPK pathway-driven cancers. The offering is expected to close on July 15, 2026, pending customary conditions.
Read more →ERAS▲ +8.9%on this news
Erasca Announces Proposed Public Offering of $500 Million of Common Stock
Erasca, Inc. announced a proposed public offering of $500 million in common stock to fund its research and development initiatives. The offering is subject to market conditions and includes an option for underwriters to purchase an additional $75 million. The proceeds will support the company's focus on therapies for RAS/MAPK pathway-driven cancers.
Read more →ERAS▲ +8.9%on this newsshared move
Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Erasca, Inc. announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015, showing a 57% overall response rate in KRAS G12X pancreatic cancer. The drug has been well-tolerated with no dose-limiting toxicities reported. The company plans to initiate registration-enabling trials in lung and pancreatic cancers in 2027.
Read more →ERAS▲ +8.4%on this news· ran to +20% by day 3
Erasca to Present at the Jefferies Global Healthcare Conference
Erasca, Inc. will participate in the Jefferies Global Healthcare Conference on June 3, 2026. The event will feature a fireside chat and one-on-one investor meetings. A live audio webcast will be available, with an archived replay for 30 days. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers.
Read more →ERASErasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)
Erasca, Inc. has announced a collaboration with Merck to evaluate ERAS-0015 in combination with KEYTRUDA for treating RAS-mutant solid tumors. The AURORAS-1 trial aims to assess the effectiveness of this combination therapy. Early data from the trial indicates promising safety and tolerability, with potential benefits in overcoming treatment resistance.
Read more →ERASErasca Reports First Quarter 2026 Business Updates and Financial Results
Erasca, Inc. provided a detailed update on its business and financial results for Q1 2026. The company reported promising results for its lead candidate ERAS-0015, showing robust efficacy and safety in treating KRAS G12X non-small cell lung cancer and pancreatic cancer. A significant cash balance supports ongoing operations into 2028. Erasca entered collaborations with Merck and Tango Therapeutics to explore combination therapies. Despite a substantial net loss for the quarter, the advancements in their clinical pipeline suggest a strong potential in the oncology market.
Read more →ERAS▲ +9.1%on this newsshared move
Erasca to Present at the Bank of America Securities Health Care Conference
Erasca, Inc. (Nasdaq: ERAS) is set to present at the 2026 Bank of America Securities Health Care Conference in Las Vegas on May 13, 2026. The event will feature a fireside chat followed by one-on-one investor meetings. A live audio webcast and an archived replay will be accessible on the company's website. Erasca focuses on therapies for RAS/MAPK pathway-driven cancers, emphasizing its commitment to erasing cancer.
Read more →ERAS▼ -48.3%on this news
Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
Erasca, Inc. announced positive preliminary Phase 1 data for its pan-RAS molecular glue, ERAS-0015, showing robust efficacy in KRAS-mutant solid tumors, particularly in non-small cell lung cancer and pancreatic cancer. The treatment demonstrated high overall response rates and was generally well-tolerated. The company anticipates further data disclosures in 2027, indicating strong potential for ERAS-0015 as a backbone therapy in future regimens.
Read more →ERAS▼ -10.9%on this news· ran to -54% by day 1shared move
Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015
Erasca, Inc. announced a conference call to discuss preliminary Phase 1 dose escalation data for ERAS-0015, a pan-RAS molecular glue. The data indicates favorable safety and tolerability, with partial responses in patients with RAS-mutant solid tumors. The call is scheduled for April 27, 2026, at 4:30 pm ET.
Read more →ERAS▼ -7%on this news
Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results
Erasca, Inc. reported positive updates for the fourth quarter and full year 2025, highlighting early clinical activity with ERAS-0015 and a successful $259 million financing. The company anticipates further data from its clinical trials in 2026, with a strong cash position expected to sustain operations into late 2028. Despite a net loss of $124.5 million, the outlook remains optimistic due to ongoing responses in RAS-mutant tumors.
Read more →ERASErasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau
Erasca, Inc. has exercised its option to expand its license agreement with Joyo Pharmatech, securing worldwide rights for its pan-RAS molecular glue, ERAS-0015, specifically including China, Hong Kong, and Macau. This expansion allows Erasca to pursue a unified global development strategy. The early clinical data for ERAS-0015 indicates its potential as a best-in-class RAS-targeting agent, with initial Phase 1 monotherapy data expected by the first half of 2026. The company remains optimistic based on promising early results across various tumor types and RAS mutations.
Read more →ERASErasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
Erasca has announced a clinical collaboration with Tango Therapeutics to evaluate ERAS-0015, a pan-RAS molecular glue, in combination with Tango's PRMT5 inhibitor, vopimetostat. This Phase 1/2 trial will focus on patients with MTAP-deleted pancreatic and non-small cell lung cancers. The collaboration aims to enhance treatment options for these patients, who currently have limited therapies available.
Read more →ERASErasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001
Erasca, Inc. announced the issuance of a U.S. patent for its pan-KRAS inhibitor ERAS-4001, providing protection until at least 2043. This patent enhances Erasca's intellectual property portfolio and supports the development of its RAS-driven cancer therapies. Initial Phase 1 data for ERAS-4001 is expected in the second half of 2026.
Read more →About Erasca, Inc.
Headquarters3115 MERRYFIELD ROW, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next ERAS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime